ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

NASDAQ:RARE • US90400D1081

20.31 USD
+0.13 (+0.64%)
Last: Feb 18, 2026, 02:45 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

RARE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. RARE may be in some trouble as it scores bad on both profitability and health. RARE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RARE has reported negative net income.
  • RARE had a negative operating cash flow in the past year.
  • In the past 5 years RARE always reported negative net income.
  • RARE had a negative operating cash flow in each of the past 5 years.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • RARE has a Return On Assets (-48.71%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -6330.70%, RARE is not doing good in the industry: 81.57% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • RARE has a better Gross Margin (84.69%) than 87.33% of its industry peers.
  • RARE's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.14%
GM growth 5Y-3.03%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RARE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of -4.86, we must say that RARE is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.86, RARE is doing worse than 61.23% of the companies in the same industry.
  • A Debt/Equity ratio of 83.39 is on the high side and indicates that RARE has dependencies on debt financing.
  • RARE has a Debt to Equity ratio of 83.39. This is amonst the worse of the industry: RARE underperforms 81.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Altman-Z -4.86
ROIC/WACCN/A
WACC8.18%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that RARE should not have too much problems paying its short term obligations.
  • RARE's Current ratio of 1.89 is on the low side compared to the rest of the industry. RARE is outperformed by 76.78% of its industry peers.
  • RARE has a Quick Ratio of 1.74. This is a normal value and indicates that RARE is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of RARE (1.74) is worse than 77.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.74
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.89% over the past year.
  • Looking at the last year, RARE shows a very strong growth in Revenue. The Revenue has grown by 20.08%.
  • The Revenue has been growing by 19.95% on average over the past years. This is quite good.
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.19%
Revenue 1Y (TTM)20.08%
Revenue growth 3Y22.81%
Revenue growth 5Y19.95%
Sales Q2Q%25.55%

3.2 Future

  • Based on estimates for the next years, RARE will show a very strong growth in Earnings Per Share. The EPS will grow by 28.68% on average per year.
  • Based on estimates for the next years, RARE will show a very strong growth in Revenue. The Revenue will grow by 30.33% on average per year.
EPS Next Y32.24%
EPS Next 2Y32.72%
EPS Next 3Y31.76%
EPS Next 5Y28.68%
Revenue Next Year16.83%
Revenue Next 2Y26.11%
Revenue Next 3Y25.5%
Revenue Next 5Y30.33%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
  • Also next year RARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • RARE's earnings are expected to grow with 31.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.72%
EPS Next 3Y31.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RARE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (2/18/2026, 2:45:08 PM)

20.31

+0.13 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners103.06%
Inst Owner Change-0.04%
Ins Owners3.24%
Ins Owner Change-0.98%
Market Cap1.96B
Revenue(TTM)672.72M
Net Income(TTM)-579.83M
Analysts85.19
Price Target66.86 (229.2%)
Short Float %9.87%
Short Ratio3.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.03%
Min EPS beat(2)-43.75%
Max EPS beat(2)11.68%
EPS beat(4)2
Avg EPS beat(4)-8.27%
Min EPS beat(4)-43.75%
Max EPS beat(4)11.68%
EPS beat(8)5
Avg EPS beat(8)-2.83%
EPS beat(12)6
Avg EPS beat(12)-4.05%
EPS beat(16)6
Avg EPS beat(16)-13.56%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.94%
Max Revenue beat(2)1.02%
Revenue beat(4)2
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-5.94%
Max Revenue beat(4)4.02%
Revenue beat(8)5
Avg Revenue beat(8)1.05%
Revenue beat(12)6
Avg Revenue beat(12)-1.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.78%
PT rev (1m)-20.16%
PT rev (3m)-21.77%
EPS NQ rev (1m)3.73%
EPS NQ rev (3m)7.93%
EPS NY rev (1m)2.75%
EPS NY rev (3m)-10.85%
Revenue NQ rev (1m)2.77%
Revenue NQ rev (3m)5.76%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF N/A
P/B 213.94
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.84
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-4.83
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS6.54
BVpS0.09
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.69%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.14%
GM growth 5Y-3.03%
F-Score2
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.7%
Cap/Sales 3.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.74
Altman-Z -4.86
F-Score2
WACC8.18%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.19%
EPS Next Y32.24%
EPS Next 2Y32.72%
EPS Next 3Y31.76%
EPS Next 5Y28.68%
Revenue 1Y (TTM)20.08%
Revenue growth 3Y22.81%
Revenue growth 5Y19.95%
Sales Q2Q%25.55%
Revenue Next Year16.83%
Revenue Next 2Y26.11%
Revenue Next 3Y25.5%
Revenue Next 5Y30.33%
EBIT growth 1Y-1.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.47%
OCF growth 3YN/A
OCF growth 5YN/A

ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ

What is the ChartMill fundamental rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RARE.


Can you provide the valuation status for ULTRAGENYX PHARMACEUTICAL IN?

ChartMill assigns a valuation rating of 1 / 10 to ULTRAGENYX PHARMACEUTICAL IN (RARE). This can be considered as Overvalued.


How profitable is ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ULTRAGENYX PHARMACEUTICAL IN (RARE) has a profitability rating of 1 / 10.


What is the financial health of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

The financial health rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 1 / 10.


Is the dividend of ULTRAGENYX PHARMACEUTICAL IN sustainable?

The dividend rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 0 / 10 and the dividend payout ratio is 0%.